The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist.
Li XX, Kumar V, Clark RJ, Lee JD, Woodruff TM.
Front Pharmacol · brief-report; journal article · DOI 10.3389/fphar.2020.591398Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för SB 290157. Visa hela publikationsregistret
Li XX, Kumar V, Clark RJ, Lee JD, Woodruff TM.
Front Pharmacol · brief-report; journal article · DOI 10.3389/fphar.2020.591398Lee JD, Taylor SM, Woodruff TM.
Br J Pharmacol · letter; comment · DOI 10.1111/bph.15264Hutamekalin P, Takeda K, Tani M, Tsuga Y, Ogawa N, Mizutani N, Yoshino S.
J Pharmacol Sci · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1254/jphs.09180fpTherien AG.
J Immunol · letter; comment · DOI 10.4049/jimmunol.174.12.7479Mathieu MC, Sawyer N, Greig GM, Hamel M, Kargman S, Ducharme Y, Lau CK, Friesen RW, O'Neill GP, Gervais FG, Therien AG.
Immunol Lett · comparative study; journal article · DOI 10.1016/j.imlet.2005.03.003Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, Settmacher B, Klos A, Erhard KF, Cousins RD, Sulpizio AC, Hieble JP, McCafferty G, Ward KW, Adams JL, Bondinell WE, Underwood DC, Osborn RR, Badger AM, Sarau HM.
J Immunol · journal article · DOI 10.4049/jimmunol.166.10.6341